SOURCE: Cohen Independent Research Group Inc.

October 10, 2012 08:30 ET

Cohen Independent Research Initiates Coverage on Medifocus Inc. With a Strong Buy Recommendation

12-Month Price Target of $.74 per Share

SAN RAFAEL, CA--(Marketwire - Oct 10, 2012) - Cohen Independent Research (CIR), Wall Street's leading independent micro-cap research firm, has announced that it has initiated coverage on Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) with a STRONG BUY recommendation and a 12-month price target of $.74 per share. CIR provides an in-depth analysis, including 5-year financial and valuation projections, on Medifocus' business and its significant growth drivers. A copy of the report is available for download at www.cohenresearch.com.

An excerpt from the report states, "Medifocus has already commercialized its enlarged Prostate (BPH) heat treatment system, 'The Prolieve®,' which was developed by the Company's scientific team. Medifocus plans to generate revenue between $40 million to $60 million from the sale of The Prolieve® in the next few years."

The Company also has an advanced medical system utlilizing the Company's Adaptive Phased Array Radar Technology (APA)-1000 for treatment of Breast Cancer. The APA-1000 uses focused and controlled microwave energy to shrink or eradicate cancerous tumours with minimal invasion and better outcomes. It is currently in the advanced phase-III clinical trial and will address the $4 billion dollar Breast Cancer treatment market.

About Cohen Independent Research

Cohen Independent Research is Wall Street's leading independent micro-cap research firm, concentrating on emerging companies with strong management teams focused on shareholder value and sustainable competitive advantage. CIR, led by renowned security analyst, Paul Cohen, this CFA analyst written research report highlight the company's market opportunity, technology, management, competition and other key differentiators that may affect their long- and short-term valuation. CIR focuses on those public companies that lack or have minimal Wall Street research analyst coverage. CIR research reports are commissioned and paid for by the companies covered, or by third parties. For more information, visit: www.cohenresearch.com.

This report/release is for informational purposes only. All information contained herein is based on public information. Cohen Independent Research Group, Inc. (CIR) complies with securities laws, regulations and ethical standards as related to our legal and compliance requirements. Certain securities regulations are cited and disclaimed in our Disclaimer. Ethical standards as related to our firm are the foundation of those securities laws and regulations we follow. Our firm is not a member of any association for other research providers. Our firm's policy is to comply with any new securities laws and regulations that might be promulgated in the future. CIR is not a registered investment advisor that distributes contracted third party independent research purchased from outside third party contracted securities analysts. To access the complete disclosure and disclaimer, download a copy of the Medifocus Inc. report at www.cohenresearch.com.

About Medifocus

Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array ("APA") technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. With the acquisition of Prolieve®, Medifocus now owns in addition, a revenue generating commercial BPH heat treatment product generating cash flow to support the development and commercialization of other catheter based or APA based external focused heat systems for targeted thermotherapy of deep seated tumors anywhere in the body. Please visit www.medifocusinc.com for more details.

Safe Harbor Statement: The Private Securities Litigation Reform Act of 1995 provides a "Safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information